ProCE Banner Activity

CAPELLA: Week 26 Results of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced Patients

Slideset Download
Conference Coverage
In patients with multidrug-resistant HIV-1 infection, lenacapavir in combination with an optimized background regimen demonstrated a high rate of virologic suppression, a clinically meaningful increase in CD4+ cell count, and no discontinuation of study therapy due to adverse events through 26 weeks.

Released: July 22, 2021

Expiration: July 21, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner